LONDON (Reuters) - Other big drugmakers may be reshaping their businesses but Novo Nordisk's focus on diabetes will get even bigger in the coming decade, according to the man most likely to be the Danish company's next boss.
Kaare Schultz, who was made deputy chief executive in January 2014 and is the frontrunner to eventually succeed 60-year-old Lars Sorensen, said diabetes was likely to account for 80-90 percent of sales in 10 years, up from 79 percent now.
14:49 Trump warns of ‘retribution’ for companies that offshore jobs, threatening 35 percent tariff18
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle21
06:01 As Schultz Steps Down, Next Starbucks CEO Brings Tech Savvy15
21:05 Starbucks Chief Howard Schultz to Step Down Next Year13